Stocks · News reference
Tyra Biosciences To Discuss Initial Clinical Results From SURF302 Phase 2 Study Evaluating Oral Dabogratinib For IR NMIBC In Conference Call And Webcast On September 9
Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $45 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and maintains $45 price target.
Tyra Biosciences shares are trading lower after the company reported worse-than-expected Q2 EPS results.